Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

Download Research Presentations Financial Disclosure Statements ISPOR 17th Annual European Congress Research Abstracts

Post on 09-Mar-2017

223 views

Category:

Documents

10 download

Embed Size (px)

TRANSCRIPT

<ul><li><p> VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A687</p><p>DISCLOSURE INFORMATION</p><p>Research Presentations Financial Disclosure Statements</p><p>The International Society for Pharmacoeconomics and Outcomes Research asked all abstract contributors to disclose fi nancial support for their research. The following fi nancial support was declared:</p><p>Copyright 2014, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.</p><p>REFERENCE CODE</p><p>FINANCIAL SUPPORT</p><p>CN1 NoneCN2 Nucletron bv, Veenendaal, The NetherlandsCN3 CTMM, Eindhoven, The NetherlandsCN4 Bristol Myers Squibb, Uxbridge, UKCP1 Genzyme, Naarden, The Netherlands; BioMarin, Dublin, IrelandCP2 NoneCP3 The Cochrane Collaboration, Oxford, UKCP4 NoneCV1 Novartis, Basel, SwitzerlandCV2 Amgen, Inc., Thousand Oaks, CA, USACV3 Novartis Pharma B.V., Arnhem, The NetherlandsCV4 Roche Products Ltd., Welwyn Garden City, UKDI1 NoneDI2 National Institute of Health, Bathesda, MD, USADI3 Abbott Diabetes Care, ROME, ItalyDI4 Instituto de Salud Carlos III PFIS-11 FIS ISCIII (320), Madrid, </p><p>Spain; DIUE, Generalitat de Catalunya (2009 SGR 1095), Barcelona, Spain; Instituto de Salud Carlos III FEDER PI13/00506, Madrid, Spain</p><p>HC1 NoneHC2 Decision Resources Group, Burlington, MA, USAHC3 LIF, Stockholm, Sweden; National Center for Priority Setting in </p><p>Health Care, Linkping, SwedenHC4 ICON, London, UKHS1 Janssen, Beerse, BelgiumHS2 NoneHS3 NoneHS4 NoneMA1 The Netherlands Organisation for Health Research and </p><p>Developmend (ZonMW), The Hague, The NetherlandsMA2 Kantar Health, Epsom, UKMA3 NoneMA4 NoneMO1 NoneMO2 Novartis Pharma AG, Basel, SwitzerlandMO3 Medical Research Council, Bristol, UK; Mapi, Houten, </p><p>The NetherlandsMO4 NoneNI1 NoneNI2 NoneNI3 NoneNI4 NonePCN1 Eisai Inc., Woodcliff Lake, NJ, USAPCN2 NonePCN4 NonePCN5 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN6 Genentech, San Francisco, CA, USAPCN7 Bristol-Myers Squibb, Rueil-Malmaison, FrancePCN8 Boehringer Ingelheim International, Ingelheim, GermanyPCN9 Bristol-Myers Squibb, Plainsboro, NJ, USAPCN10 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN11 F. Hoffmann - La Roche AG, Basel, SwitzerlandPCN12 Janssen, Beerse, BelgiumPCN13 NonePCN14 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN15 Sobi, Solna, SwedenPCN16 Merck Serono, Feltham, UK; Merck Serono, Darmstadt, UKPCN20 Eli Lilly and Company, Windlesham, UKPCN21 Janssen-Cilag, Neuss, GermanyPCN22 National Institute of Health Research, London, UKPCN23 Janssen-Cilag, High Wycombe, UKPCN24 Janssen-Cilag BV, Tilburg, The Netherlands; Janssen-Cilag AB, </p><p>Sollentuna, Sweden; Janssen-Cilag GMBH, Neuss, GermanyPCN25 Novartis, Basel, SwitzerlandPCN26 Novartis, Moscow, RussiaPCN27 Roche Farmacutica Quimica, Amadora, PortugalPCN28 NonePCN29 GlaxoSmithKline, Zeist, The NetherlandsPCN30 IPSEN, Boulogne-Billancourt, FrancePCN31 NonePCN32 NonePCN33 Bristol-Myers Squibb, Rueil Malmaison, FrancePCN34 NonePCN35 NonePCN36 None</p><p>REFERENCE CODE</p><p>FINANCIAL SUPPORT</p><p>PCN37 NonePCN38 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN39 Roche Farmacutica Quimica, Amadora, PortugalPCN40 Janssen Pharmaceuticals, Inc., Raritan, NJ, USAPCN41 Sanofi -Aventis, Warsaw, PolandPCN42 Bayer Healthcare Pharmaceuticals, Inc., Wayne, NJ, USAPCN43 NonePCN44 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAPCN45 NonePCN46 Janssen, Sao Paulo, BrazilPCN47 Meda Pharma, Frankfurt, GermanyPCN48 Pfi zer, Mexico, MexicoPCN49 NonePCN50 NonePCN51 NonePCN52 NonePCN53 Eisai, Woodcliff Lakes, NJ, USAPCN54 Green Cross, Yong-In, South KoreaPCN55 Pfi zer, Inc., So Paulo, BrazilPCN56 Genomic Health, Geneva, SwitzerlandPCN58 GlaxoSmithKline d.o.o., druba za promet s farmacevtskimi </p><p>izdelki, Ljubljana, Slovenia, Ljubljana, SloveniaPCN59 KWF Cancer Research, Amsterdam, The NetherlandsPCN60 Teva Pharmaceutical, Philadelphia, PA, USAPCN61 National Cancer Institute, Boulogne Billancourt, FrancePCN62 French National Cancer Institute, Boulogne Billancourt, FrancePCN63 Roche Products Limited, Welwyn Garden City, UKPCN64 MSD Italy, Rome, ItalyPCN65 NonePCN66 NonePCN67 NonePCN68 GlaxoSmithKline Slovakia s.r.o, Bratislava, Slovak RepublicPCN69 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPCN70 Laboratrios Pfi zer Lda, Lisbon, PortugalPCN71 NonePCN72 Pfi zer, Mexico, MexicoPCN73 NonePCN74 NonePCN75 NonePCN76 NonePCN77 NonePCN78 NonePCN79 Health Research Board, Dublin, IrelandPCN80 NonePCN81 2Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San </p><p>Francisco, CA, USAPCN82 NonePCN83 Sanofi Pasteur MSD, Maidenhead, UKPCN84 Eisai, Woodcliff Lake, NJ, USAPCN85 Pfi zer, New York, NY, USAPCN86 Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Ingelheim, </p><p>GermanyPCN87 UERJ, Rio de Janeiro, Brazil; UFF, Niteri, BrazilPCN88 Pfi zer, Mexico, MexicoPCN89 The Ministry of Science and Education of the Republic of Serbia </p><p>for Grant N175014, Belgrade, Serbia and MontenegroPCN90 Amgen Inc., Thousand Oaks, CA, USAPCN91 NonePCN92 NonePCN93 Innovative Medicine Initiative, Brussels, BelgiumPCN94 Department of Health, Canberra, AustraliaPCN95 the Center for Translational Molecular Medicine, Eindhoven, </p><p>The NetherlandsPCN96 NonePCN97 Norgine Ltd., Uxbridge, UKPCN98 GlaxoSmithKline S.R.L., Bucharest, RomaniaPCN99 NonePCN100 Productos Roche, Bogota, ColombiaPCN101 BMS Spain, Madrid, SpainPCN102 NonePCN103 Janssen, Panama, PanamaPCN104 Novartis, Camberley, UKPCN105 Genesis Pharma, Athens, GreecePCN106 Amgen, Zug, SwitzerlandPCN107 GSK, Tres Cantos (Madrid), Spain</p></li><li><p>A688 VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9</p><p>REFERENCE CODE</p><p>FINANCIAL SUPPORT</p><p>PCN108 AstraZeneca, Mexico City, MexicoPCN109 GlaxoSmithKline, Mississauga, ON, CanadaPCN110 Amgen, Athens, GreecePCN111 Amgen, Athens, GreecePCN112 Roche Hungary, Budapest, HungaryPCN113 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPCN114 NonePCN115 Novartis Pharmaceuticals, East Hanover, NJ, USAPCN116 GlaxoSmithKline Biological S.A., Rixensart, Belgium; </p><p>GlaxoSmithKline Slovakia, Bratislava, Slovak RepublicPCN117 Novartis, Camberley, UKPCN118 NonePCN119 BMBF, Bonn, GermanyPCN120 Janssen, Panama, PanamaPCN121 Janssen, panama, PanamaPCN122 Novartis, Moscow, RussiaPCN123 Covance Inc., London, UKPCN124 NonePCN125 NonePCN126 NonePCN127 NonePCN128 NonePCN129 Helmholtz Zentrum Mnchen, Neuherberg, GermanyPCN130 Sanofi Pasteur MSD, Lyon, FrancePCN131 NonePCN132 Takeda Pharmaceuticals, Zurich, Switzerland; T.I. Salud, Mexico </p><p>City, MexicoPCN133 NonePCN134 NonePCN135 NonePCN136 Pfi zer China, Shanghai, ChinaPCN137 University of Jordan, Amman, JordanPCN138 Merck Serono, Feltham, UK; Merck Serono, Darmstadt, UKPCN140 NonePCN141 NonePCN142 Psicofarma, Mexico City, MexicoPCN143 Oncotyrol, Innsbruck, AustriaPCN144 Oncotyrol, Innsbruck, AustriaPCN145 Takeda Pharma, Solna, SwedenPCN146 Laboratrios Pfi zer Lda., Porto Salvo, PortugalPCN147 NonePCN148 Carl-Zeiss, Oberkochen, GermanyPCN149 NonePCN150 Novartis, UKPCN151 Roche Hellas, Athens, GreecePCN152 Roche Pharmaceuticals, So Paulo, BrazilPCN153 NonePCN154 Grindex, Moscow, RussiaPCN155 Mundipharma GesmbH. Austria - organization unit Czech </p><p>Republic, Prague, Czech RepublicPCN156 Boehringer Ingelheim, Alkmaar, The NetherlandsPCN157 National Institute of Health Research, London, UKPCN158 Celgene International Sarl, Boudry, SwitzerlandPCN159 NonePCN160 NonePCN161 Celgene, Summit, NJ, USAPCN162 NonePCN163 Bristol-Myers Squibb, Rueil Malmaison, FrancePCN164 NonePCN165 NonePCN166 AdRes, Turin, ItalyPCN167 German Federal Ministry of Education and Research, Berlin, </p><p>GermanyPCN168 AstraZeneca UK Ltd., Luton, UKPCN169 Amgen Inc., Thousand Oaks, CA, USAPCN170 CTMM, Eindhoven, The NetherlandsPCN171 NonePCN172 NonePCN173 Personalized Medicine Partnership for Cancer (PMPC), </p><p>Montreal, QC, CanadaPCN174 Amgen Inc., Thousand Oaks, CA, USAPCN175 NonePCN176 NonePCN177 UBC, Dorval, CanadaPCN178 AstraZeneca, Alderley Park, UKPCN179 Oxford PharmaGenesis Ltd., Tubney, Oxford, UKPCN180 Eisai Inc., Woodcliff Lake, NJ, USAPCN181 GILEAD, London, UKPCN182 AstraZeneca, Macclesfi eld, UKPCN183 DIUE de la Generalitat de Catalunya (2009 SGR 1095), Barcelona, </p><p>Spain; Catalan Agency for Health Information, Assessment and Quality (grant AATRM 436/05/2008), Barcelona, Spain</p><p>PCN184 Roche, Boulogne Billancourt, FrancePCN185 National Institute of public health and the environment, Bilthoven, </p><p>The NetherlandsPCN186 Institut de Recherche Pierre Fabre, Boulogne-Billancourt, FrancePCN187 None</p><p>REFERENCE CODE</p><p>FINANCIAL SUPPORT</p><p>PCN188 NonePCN189 NonePCN190 NIHR School for Primary Care Research, London, UKPCN191 Astellas Pharma a/s, Kastrup, DenmarkPCN192 NonePCN193 NonePCN194 Amgen (Europe) GmbH, Zug, SwitzerlandPCN195 NonePCN196 The Netherlands Organisation for Health Research and </p><p>Development, The Hague, The Netherlands; Roche The Netherlands, Woerden, The Netherlands; Pfi zer The Netherlands, Capelle a/d IJssel, The Netherlands</p><p>PCN197 Genentech, South San Francisco, CA, USAPCN198 Takeda, Roskilde, DenmarkPCN199 GlaxoSmithKline, Cambridge, UKPCN200 LifeCell Corporation, Bridgewater, NJ, USAPCN201 Ipsen Pharma GmbH, Ettlingen, GermanyPCN202 Janssen Pharmaceuticals, Neuss, GermanyPCN203 Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Ingelheim am </p><p>Rhein, GermanyPCN204 Health Research Board, Dublin, IrelandPCN205 Roche, Basel, SwitzerlandPCN206 Medivation, Inc., San Francisco, CA, USA; Astellas Pharma Global </p><p>Development, Inc., Northbrook, IL, USAPCN207 NonePCN208 NonePCN209 NonePCN210 University of the Basque Country, UPV / EHU, Basque Country, </p><p>SpainPCN211 NonePCN212 NonePCN213 NIHR, Leeds, UKPCN214 NonePCN215 NonePCN216 NonePCN217 NonePCN218 Main Association of Austrian Health Security Institutions, Vienna, </p><p>AustriaPCN219 Eli Lilly Italy, Florence, ItalyPCN220 NonePCN221 Roche F.Hoffmann-La Roche Ltd., Moscow, RussiaPCN222 Novartis Hellas, Metamorfosi, Attica, Athens, GreecePCN223 NonePCN224 NonePCN225 Decision Resources Group, Burlington, MA, USAPCN226 NonePCN227 Eli Lilly and Company, Indianapolis, IN, USAPCN228 NonePCN229 NonePCN230 NonePCN231 NonePCN232 AstraZeneca, Zoetermeer, The NetherlandsPCN233 MUSC Medication Safety Program, Charleston, SC, USAPCN234 Genentech, Inc., South San Francisco, CA, USAPCN235 NonePCN236 GE Healthcare, Riyadh, Saudi ArabiaPCN237 NonePCN238 Amgen CEE Headquarters, Vienna, AustriaPCN239 NonePCN240 GlaxoSmithKline Biologicals S.A., Rixensart, BelgiumPCN241 NonePCN242 NonePCN243 Boehringer Ingelheim, Bracknell, UKPCN244 NonePCN245 Amgen CEE Headquarters, Vienna, AustriaPCN246 NonePCN247 Alliance Life Sciences Consulting Group, Somerset, NJ, USAPCN248 Roche Pharma AG, Grenzach-Wyhlen, GermanyPCN249 NonePCN250 NonePCN251 NonePCN252 Roche, Welwyn Garden City, UKPCN253 IMS Consulting Group, Munich, GermanyPCN254 NonePCN255 NonePCN256 NonePCN257 NonePCN258 NonePCN259 NonePCN260 Costello Medical Consulting, Cambridge, UKPCN262 NonePCN263 Pharmaceutical Research and Manufacturers of America, </p><p>Washington, DC, USAPCN264 So Paulo Research Foundation (FAPESP), Sao Paulo, BrazilPCN265 NonePCN266 Quintiles Consulting, Reading, UKPCN267 None</p></li><li><p> VA L U E I N H E A LT H 1 7 ( 2 0 1 4 ) A 6 8 7 - A 6 9 9 A689</p><p>REFERENCE CODE</p><p>FINANCIAL SUPPORT</p><p>PCN268 Evidera, London, UKPCN269 European Commission, Brussels, The NetherlandsPCN270 Ministry of Health and Welfare, Sejong, South KoreaPCN271 Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Ingelheim, </p><p>GermanyPCN272 NonePCN273 Genomic Health, Inc., Redwood City, CA, USAPCN275 The Netherlands Organisation for Health Research and </p><p>Development, the Hague, The NetherlandsPCN276 NonePCN277 Oncotyrol, Innsbruck, Austria; Austrian Federal Ministries </p><p>of BMVIT/BMWFJ, Vienna, Austria; Tiroler Zukunftsstiftung/Standortagentur Tirol, Innsbrucker, Austria</p><p>PCN278 NonePCN279 ZonMw, Den Haag, The NetherlandsPCN280 AstraZeneca, London, UKPCN281 NonePCV1 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV2 Daiichi Sankyo Europe GmbH, Munich, GermanyPCV3 NonePCV4 U.S. Food and Drug Administration, Silver Spring, MD, USAPCV5 NonePCV6 Bayer Pharma AG, Berlin, GermanyPCV7 NonePCV8 NonePCV9 Amgen, Thousand Oaks, CA, USAPCV10 Medtronic Inc., Santa Rosa, CA, USAPCV11 Medtronic, Minneapolis, MN, USAPCV12 NonePCV14 BMS, Princeton, NJ, USA; Pfi zer, New York, NY, USAPCV15 National Evidence-based Healthcare Collaborating Agency, Seoul, </p><p>South KoreaPCV16 Proteus Digital Health, Redwood City, CA, USAPCV17 AstraZeneca, Mlndal, SwedenPCV18 Boehringer Ingelheim, Paris, FrancePCV19 Pfi zer Ltd., Surrey, UKPCV20 NonePCV21 Bayer Hispania, Barcelona, SpainPCV22 Pierre Fabre Mdicament, Boulogne, FrancePCV23 Merck Shape &amp; Dohme, Hoddesdon, UKPCV24 NonePCV25 Bristol-Myers Squibb, Princeton, NJ, USAPCV26 BMS, Rueil Malmaison, FrancePCV27 National Heart, Lung, and Blood Institute, Bethesda, MD, USA; </p><p>American Heart Association, Dallas, TX, USAPCV28 Menarini, Florence, ItalyPCV29 NonePCV30 Eli Lilly and Company, Indianopolis, IN, USAPCV31 RAGS, Selangor, MalaysiaPCV34 NonePCV35 Amgen Inc., Thousand Oaks, CA, USAPCV36 Pfi zer, S.L.U., Madrid, SpainPCV37 Servier Poland Sp. z o.o., Warsaw, PolandPCV38 Proteus Digital Health, Redwood City, CA, USAPCV39 Bristol-Myers Squibb Italy, Rome, Italy; Pfi zer Italia, Rome, ItalyPCV40 NonePCV41 Abbott Hellas, Athens, GreecePCV42 Ipsen Pharma, Ettlingen, GermanyPCV43 NonePCV44 NonePCV45 The Medicines Company, Parsippany, NJ, USAPCV46 NonePCV47 NonePCV48 Abbott Vascular, Rungis, FrancePCV49 diaDexus, San Francisco, CA, USAPCV50 Heart and Stroke Foundation of Canada, Toronto, ON, CanadaPCV51 NonePCV52 NonePCV53 Sorin Group Italia, Milano, ItalyPCV54 National Health and Medical Research Council, Canberra, </p><p>AustraliaPCV55 NonePCV56 Medtronic, Inc., Mounds View, MN, USAPCV57 Medtronic, Sesto S.Giovanni, Italy; Medtronic, Meerbusch, </p><p>Germany; Medtronic, Madrid, Spain; Medtronic, Warsaw, Poland; Medtronic, Maastricht, The Netherlands</p><p>PCV58 Ministry of Health of the Czech Republic, Prague, Czech RepublicPCV59 Boehringer-Ingelheim France, Paris, FrancePCV60 Bristol-Myers Squibb, Rueil-Malmaison, France; Pfi zer, Paris, </p><p>FrancePCV61 CSL Behring, King of Prussia, PA, USAPCV62 Medtronic Iberia, Madrid, SpainPCV63 NonePCV64 Novartis Pharma AG, Basel, SwitzerlandPCV65 NonePCV66 Gedeon Richter, Budapest, HungaryPCV67 BMBF, Bonn, Germany</p><p>REFERENCE CODE</p><p>FINANCIAL SUPPORT</p><p>PCV68 Medtronic spa, Sesto San Giovanni (MI), ItalyPCV69 Novartis, Dublin, IrelandPCV70 CSL Behring, King of Prussia, PA, USAPCV71 NonePCV72 CTMM, Eindhoven, The Netherlands; Dutch Heart Foundation, </p><p>The Hague, The Netherlands; Dutch Organisation for Health Research and Healthcare Innovation, The Hague, The Netherlands</p><p>PCV74 NonePCV75 Institute of Cardiology, Warsaw, PolandPCV76 Medtronic Italia S.p.A., Sesto San Giovanni, ItalyPCV77 NonePCV78 Baxter, Utrecht, The NetherlandsPCV79 Boehringer-Ingelheim, Bogota, ColombiaPCV80 Vifor Pharma, Athens, GreecePCV81 NonePCV82 Servier, Madrid, SpainPCV83 Bristol-Myers Squibb Italy, Rome, Italy; Pfi zer Italia, Rome, ItalyPCV84 University Sains Malaysia, Penang, MalaysiaPCV85 NonePCV86 AstraZeneca, Hong Kong, Hong KongPCV87 National...</p></li></ul>